The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
This article connects the dots ref in sewage detection tech. Doesn’t directly say so, but infers it.
https://www.bloomberg.com/news/articles/2020-09-07/covid-19-patients-may-have-prolonged-gut-infection-study-finds
Linked to DDDD work too.
Having looked at these images a couple of things stand out. This is a very , very high level proposal that is very light on detail. Like something understandable enough to get the Cabinet to sign off for more working up. There is a focus on the known commercial Pharma entities, not very much evidence of knowing what else is going on e.g. with Avacta, ODX etc. Also traditional retail outlets. Also no mention of the RTC that I could find. Seems to me this may be compiled by people not wholly in contact with what if actually going on, nor considering hard enough breaking out of traditional moulds. Still if it truly does become all encompassing of the pharma and bioscience sector, large and small, all well and good.
As an example of App look at this Cardiff based crew with LFD + Tech product
https://bondhealth.co.uk/
Take a look at the connections of this company and its tech in the world of LFD.
https://bondhealth.co.uk/
Look particularly at their News and Blog pages.
Could be communication satellite manufacturers, handheld mobile device manufacturers and 5G infrastructure builders.
Sorry but you cannot compare the third stage of a proof of concept series of experiments as here, with a full on, phase 3 clinical trial on patients as per SNG. That is not to say that each action in their context are not important and able to influence market prices, but they are not at all comparable imho.
If a compound shows enough efficacy at P2 then P3 can be waived because of the amount of benefit to so many patients that would be foregone. P3 trials have been stopped and treatments pushed to market when they show major and significant benefits to patients. It is deemed unethical to slavishly follow a trial and not treat patients..
So imagine if this applied to GDR! Why getting it right is so important.
https://www.publictechnology.net/articles/news/nhs-suspends-use-coronavirus-test-kits-over-‘safety’-issue
Why getting it right is important.
https://www.publictechnology.net/articles/news/nhs-suspends-use-coronavirus-test-kits-over-‘safety’-issue
Just to point out a CE approval indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area. It says nothing at all about whether the test is any good or not. That’s what further approvals are about - test efficacy.
Just watched a TV report on the fact that around 50% of people recovering from CV19 have prolonged problems. Shortage of breath among them. Others are fatigue, cognitive loss. Sounds like they need some treatment assistance in the recovery period. One case was still suffering 105 days after coming down with CV19.
We must remember the World is the market, not just the UK. Good sales and marketing activity, with PR on how commercials go forward with a continuous international flavour will keep the focus on, despite how the UK moves.
Key issue is which of the three main components that make up R has moved? Hospital, Care Home or Community? What is regional variation? R also lags today by a week or so. No need to panic I’d say.
I meant covidclear email! Lol! Detail indeed!
I mailed the hvivoclear email this afternoon pointing out the same thing. Attention to detail matters!
Also in Greek mythology, Medusa also called Gorgo, was one of the three monstrous Gorgons, generally described as winged human females with living venomous snakes in place of hair. Those who gazed into her eyes would turn to stone. ThinK I prefer the previous definition!!